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Abstract
There is increasing discussion of a potential role for statins in the management of sepsis. A search of PubMed, Embase, Scopus and the
Cochrane Library databases was performed by combining the terms ‘statins’, ‘infection’, ‘sepsis’, ‘bacteraemia’, ‘pneumonia’, and ‘ICU
infections’. A total of 22 studies were retrieved, which included 177 260 people and compared clinical outcomes between 51 193 statin
users and 126 067 non-statin users. Nineteen were cohort studies (seven prospective and 12 retrospective), two were retrospective
case–control studies, and one was a randomized controlled study. Nine studies examined the use of statins in sepsis, four in commu-
nity-acquired pneumonia (CAP), three in bacteraemia, and three in post-operative patients. Mortality data were presented in 15 studies;
in ten, mortality was lower among statin users (three of six sepsis studies, ﬁve of six CAP studies, and two of three bacteraemia stud-
ies). In four studies, there was no difference in mortality (two of six sepsis studies, one of six CAP studies, and one of three bactera-
emia studies) and in one study there was increased mortality among septic intensive-care unit patients receiving statins. Five of the nine
studies that examined the risk of developing sepsis/infection as a primary outcome (six of nine sepsis studies and all studies in the post-
operative setting) found a decreased risk among statin users, whereas the remaining studies found no difference. Irrespective of their
design (matched vs. non-matched), the majority of the studies suggested that statins have a beneﬁcial effect on the outcome of infection;
however, their observational design does not allow us to draw ﬁrm conclusions. The clinical beneﬁt of statin therapy in sepsis remains
to be determined by ongoing randomized controlled trials.
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Introduction
Sepsis is a common, expensive and frequently fatal clinical
problem. Previous studies have estimated that more than
750 000 episodes of severe sepsis (300 cases per 100 000
population) occurred in the USA in 1995 and approximately
215 000 of the patients died [1]. At that time, the average
cost per case was $22 100, and this resulted in an economic
burden of nearly $17 billion annually in the USA alone [1].
Disturbingly, the incidence of sepsis and the number of sep-
sis-related deaths appeared to be increasing by 8.7% each
year from 1979 through 2000 [2], and there is no sign of a
reversal of this trend.
Sepsis is a highly complex inﬂammatory syndrome in
which multiple cellular and humoral pathways are involved.
Merely interfering with one of these pathways may be insufﬁ-
cient to arrest the whole inﬂammatory process, and this may
partly explain why most of the adjunctive therapies devel-
oped for severe sepsis have shown disappointing results in
rigorous clinical trials [3]. In fact, treatment with activated
protein C is the only adjunctive therapy shown to be
effective [4]; the initial enthusiasm about the role of steroids
[5] has been tempered by the negative ﬁndings of the
CORTICUS study [6].
Statins are lipid-lowering drugs that inhibit 3-hydroxy-
3-methylglutaryl coenzyme A reductase and reduce total
cholesterol, low-density lipid cholesterol, apolipoprotein B
and triglyceride levels. These drugs have an excellent track
record in reducing cardiovascular mortality among patients
with and without coronary artery disease [7]. In the last dec-
ade, it was shown that statins possess a multitude of pleio-
tropic anti-inﬂammatory/immunomodulatory effects that are
independent of their lipid-lowering effect; these immunomod-
ulatory effects appear to be mediated through the blockade
of mevalonate synthesis. Mevalonate is the precursor of
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multiple isoprenoid products that, in turn, facilitate the intra-
cellular trafﬁcking of cellular membrane proteins with signal-
ling functions. For example, the inactivation of small GTP-
binding proteins, which work as molecular on/off switches
for cytoplasmic kinases—nuclear factor-jB, the mitogen-acti-
vated protein kinase family, and protein kinase B—leads to
attenuation of this proinﬂammatory signalling and moderation
of the maladaptive inﬂammatory response. Although a
detailed discussion of the mechanisms by which statins may
inﬂuence sepsis-associated inﬂammation is beyond the scope
of this review, it should be noted that statins lower the pro-
inﬂammatory tendency of leukocytes and monocytes,
enhance T-helper cell function, directly suppress major histo-
compatibility class II antigen expression by macrophages,
reduce the release of cytokines, chemokines and acute-phase
reactants, impair the expression of adhesion molecules such
as P-selectin, limit endothelial cell activation and improve
endothelial function by reducing the inducible nitric oxide
synthase/endothelial constitutive nitric oxide synthase ratio,
modulate coagulation by blunting tissue factor and plasmino-
gen activator inhibitor-1 expression and enhancing protein C
function, display antioxidant and antiapoptotic properties,
and activate haem oxygenase, an inducible, heat shock cyto-
protective protein [8].
The pleiotropic actions of statins provided the rationale
for investigating their role in sepsis, not only in vitro, but also
in animal and clinical studies. The intense interest in their
use for the management of septic patients has led to a series
of publications with contradictory results that leave the clini-
cians hopeful but confused. Thus, we sought to critically
examine the relevant evidence from studies regarding the
role of statin use in the management of sepsis.
Literature search
We updated and extended our previous electronic search
[9] through PubMed, Embase, Scopus and the Cochrane
Library databases using the following key terms: ‘statins’,
‘infection’, ’sepsis’, ‘bacteraemia’, ‘pneumonia’, and ‘ICU infec-
tions’. We focused on peer-reviewed, full-text, observational
cohort or case–control studies and randomized controlled
trials that compared infection-related outcomes (i.e. hospital
mortality) among patients receiving or not receiving statins.
We did not, a priori, exclude any speciﬁc subpopulation of
patients from our dataset. For the purpose of this review,
we focused on bacterial infections, and excluded studies
investigating the effect of statins on viral (i.e. inﬂuenza and
human immunodeﬁciency virus infection), fungal and proto-
zoan infections. We also excluded studies that were experi-
mental or laboratory-based. On the other hand, we set no
time or language limit on our search, and scanned all refer-
ences from identiﬁed articles for additional relevant informa-
tion.
We extracted and tabulated data concerning study design,
patient settings, type of infection (sepsis, bacteraemia, pneu-
monia, and postoperative infections), number of included
patients, and primary and secondary clinical outcomes. We
also focused on the methodological aspects of the included
studies, especially the inclusion of propensity scoring as an
attempt to control for confounding bias.
Finally, we searched the online registry of randomized
controlled trials (RCTs) of the US National Institutes of
Health (http://www.clinicaltrials.gov) and the Current Con-
trolled Trials website (http://www.controlled-trials.com) for
relevant studies. The end date of the review was 15 Decem-
ber 2008.
Available Relevant Studies
We retrieved 22 studies [10–31] regarding the use of statins
in patients at risk of infection that included a total number
of 177 260 individuals (51 193 statin users and 126 067 non-
statin users). The study cohort included 72 842 admitted
patients and 104 418 individuals who were followed in the
outpatient setting.
Before discussing these studies, it is necessary to brieﬂy
present ﬁve additional studies [32–36] that we excluded for
various reasons from further analysis; some of them [32–
34] have been included in similar reviews of the subject.
Frost et al. [32] conducted a matched-cohort study and a
separate case–control study (including 397 inﬂuenza deaths),
and found a signiﬁcantly reduced risk of unspeciﬁed pneu-
monia/inﬂuenza death among moderate-dose statin users.
However, the authors did not discriminate between viral
and bacterial pneumonia, based their diagnosis on assigned
computerized codes, and did not verify compliance with the
prescribed medications. In a retrospective cohort study,
Schmidt et al. [33] showed that patients who developed
multiple organ dysfunction syndrome under statin treatment
had lower 28-day mortality rates as well as lower hospital
mortality rates. Unfortunately, they did not specify whether
infection was the underlying cause of multiple organ dys-
function syndrome. Ishida et al. [34], by implementing a
novel idea, designed a population-based analysis using data
from marketing surveys and government reports on mortal-
ity; they considered the statin use as expressed by statin
sales per capita in the aged population and the mortality
from major causes of death among 47 prefectures in Japan,
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and found a correlation between statin sales and decrease
in mortality (p <0.05).
Donnino et al. [35] performed a secondary analysis of a pro-
spective, observational study conducted at an urban, academic
hospital emergency department, and found that, among 2036
patients with suspected infection, patients who received sta-
tins had a statistically signiﬁcant lower mortality rate than
those who did not (1.9% vs. 4.4%; p 0.02). The ﬁndings of this
study have been presented only in an abstract. Finally, Ali and
Buth [36] studied 5469 patients (3555 were receiving statins
and 1914 were not) who underwent coronary artery bypass
grafting (CABG), valve or combined CABG/valve surgery, and
found that the unadjusted rate of sepsis and/or deep sternal
wound infections was lower among statin users (2.3% vs. 4.1%;
p 0.0002); however, when propensity score analysis was used
to match the two subgroups of patients (1443 receiving statins
and 1443 not receiving statins), statin use was not associated
with a reduction in sepsis and/or deep sternal wound infec-
tions (OR 0.7; 95% CI 0.5–1.1; p 0.1), or mortality rate
(36.3% in both groups; p 1.0). These ﬁndings have also been
presented in abstract form only (the manuscript is in prepara-
tion; I. Ali, personal communication).
Nineteen of the 22 included studies were cohort studies
(seven prospective [14,15,18,21,23,26,29] and 12 retrospec-
tive [10,11,13,16,17,19,20,25,27,28,30,31]) and two were ret-
rospective case–control studies [22,24]. We identiﬁed only
one randomized controlled trial [12]. The evaluable studies
were divided into four groups according to the type of infec-
tion and tabulated accordingly: (i) studies regarding the use
of statins in patients with sepsis or at risk of sepsis (Table 1);
(ii) studies including patients with community-acquired pneu-
monia (CAP) (Table 2); (iii) studies referring to patients with
bacteraemic infections (Table 3); and (iv) studies that focused
on postoperative infections (Table 4).
Studies examining the use of statins in patients with sepsis
or at risk of sepsis
Nine studies were included in this group [10–18]. The ran-
domized controlled trial by Tseng et al. [12] randomized 80
patients with subarachnoid haemorrhage to receive either
pravastatin or placebo for up to 14 days, and showed that,
although more patients in the pravastatin group experienced
sepsis (pneumonia or catheter-related infections), this differ-
ence was not statistically signiﬁcant. It is of interest that sta-
tin use seemed to confer an impressive reduction in sepsis-
related mortality (6.25% as compared with 71.43%; log-rank
test; p <0.001). Although this study had a randomized design,
the small number of patients (40 in each group) and the fact
that sepsis incidence and the associated mortality were not
the primary outcomes preclude ﬁrm conclusions.
The other eight studies were cohort studies (three pro-
spective [14,15,18] and ﬁve retrospective [10,11,13,16,17])
and included from 53 [13] up to 69 168 [17] patients
(41 145 statin users and 44 750 non-statin users). Propen-
sity-matched subcohorts were used in three of the eight
cohort studies [14,15,17], and all of these studies reported
positive ﬁndings. Speciﬁcally, statin use was associated with
signiﬁcantly lower numbers of sepsis-related hospitalizations
in two of these studies [14,17] and decreased infection-
related mortality in one study [15]. As far as the ﬁve
studies that had a non-matched design are concerned
[10,11,13,16,18], statin use was associated with decreased
sepsis/infection rates in two studies [13,18] and with no
difference in one study [16]; the other two studies did not
provide data on this outcome [10,11]. In addition, statin use
was associated with decreased overall 30-day or hospital
mortality in one study [10], no difference in two studies
[11,13], and increased mortality in one study [16]. In this
study, hospital mortality was signiﬁcantly higher in statin-
treated patients, even after adjustment for the expected
mortality risk deﬁned by the APACHE II score (observed/
expected ratio: 1.53/1.17). The authors of the study hypothe-
sized that ‘underlying clinical conditions were insufﬁciently
considered in mortality predictors’. In conclusion, the studies
that focused on sepsis and implemented propensity score
analysis and the randomized controlled trial reported ﬁndings
that were at least as positive as those of the studies without
matched design.
Studies examining the use of statins in patients with CAP
In the second group, seven studies were included [19–25];
ﬁve of them were cohort studies (two prospective [21,23]
and three retrospective [19,20,25]) and two were retrospec-
tive case–control studies [22,24]. The individual study sample
size ranged from 787 [25] up to 29 900 patients [19] (includ-
ing 9603 statin users and 60 290 non-statin users).
In the only study with a non-matched design, it was found
that statin use was associated with signiﬁcantly lower 30-day
mortality [21]. Propensity-matched subcohorts were used in
four studies [19,20,23,25]; statin use at presentation was
associated with decreased 30-day mortality in three of them
[19,20,25] and no difference in one [23]. In addition, in both
case–control studies [22,24], it was found that current statin
use was associated with a reduced overall risk of pneumonia
or fatal pneumonia. Overall, statin use was associated with
decreased mortality in ﬁve studies [19–22,25] and no differ-
ence in one study [23]. In addition, statin use was shown to
reduce the risk of complicated parapneumonic effusion and
empyema in one study, although it had no effect on the
requirements for inotropic support or mechanical ventilation
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[21], whereas in another study there was no discernible
effect on pulmonary complications [19]. In summary, all
studies but one examining the effect of statin use on CAP
reported positive results, and the study design seemed to
have no effect on the results.
Studies examining the use of statins in patients with
bacteraemia
In the third group, three studies were included [26–28]; all
of them were cohort studies (one prospective [26] and two
retrospective [27,28]). Propensity-matched analysis was not
used in any of these studies. The individual study sample size
ranged from 388 [28] up to 5353 patients [26] (including 277
statin users and 5902 non-statin users). Both hospital mortal-
ity and bacteraemia-attributable mortality were lower among
statin users in two studies [27,28]. In one of them, the inten-
sive-care unit (ICU) admission rate due to bacteraemia was
not signiﬁcantly different between statin and non-statin users
[28]. In the third study, the 30-day mortality was not lower
among statin users [26]; however, among the 30-day survi-
vors, statin use was associated—for reasons that are
unclear—with substantially decreased mortality up to
180 days after the bacteraemia episode.
Studies examining the use of statins for infection prevention
in the postoperative setting
In the fourth group, three studies were included [29–31]; all
of them were cohort studies (one prospective [29] and two
retrospective [30,31]). The study sample size ranged from
1934 [30] up to 10 782 patients [31] (including 4325 statin
TABLE 3. Clinical evidence regarding the use of statins in bacteraemia
Study Study design Patients’ settings Study groups Primary outcome Secondary outcomes
[26] Observational
cohort
study based on
prospective
registration
5353 adult patients
hospitalized with
bactaeremia
SUs: 176
NSUs: 5177
The 30-day mortality in SUs was
similar to that in NSUs (20.0% vs.
21.6%; adjusted mortality rate
ratio 0.93; 95% CI
0.66–1.30; p 0.66)
Among 30-day survivors, SUs
experienced a substantially
decreased mortality up to
180 days after the bacteraemia
(8.4% vs. 17.5%; adjusted mortality
rate ratio 0.44; 95% CI 0.24–0.80;
p 0.05)
[27] Retrospective
cohort study
438 bacteraemic patients
admitted to a single
acute-care general hospital
SUs: 66
NSUs: 372
Overall hospital mortality was
lower among SUs (10.6% vs.
23.1%; OR 0.4; 95% CI 0.17–0.9;
p 0.022)
Bacteraemia-attributable mortality
was also lower among SUs (6.1%
vs. 18.3%; OR 0.29; 95% CI
0.1–0.82; p 0.014)
[28] Retrospective
cohort study
388 patients with bacteraemic
infections due to aerobic
Gram-negative bacilli and
Staphylococcus aureus admitted
to a single VA Medical Center
SUs: 35
NSUs: 353
SUs experienced a lower hospital
mortality rate (6.0% vs. 28.0%;
p 0.002)
Bacteraemia-attributable mortality
was also lower among SUs (3.0%
vs. 20.0%; p 0.01)
The ICU admission rate while the
patients had bacteraemia was not
signiﬁcantly different between SUs
and NSUs (17.1% vs. 19.3%)
ICU, intensive-care unit; NSU, non-statin user; SU, statin user; VA, Veterans Affairs.
TABLE 4. Clinical evidence regarding the use of statins for preventing infections in the postoperative setting
Study Study design Patients’ settings Study groups Primary outcome Secondary outcomes
[29] Prospective
cohort study
Propensity score
was estimated
2497 adult patients who
underwent isolated CABG
Serious infection morbidity
consisted of sepsis syndrome,
septic shock, or mediastinitis
SUs: 1835
NSUs: 662
SUs: 654
NSUs: 654
SUs and NSUs had similar rates of
serious infections (1.7% vs.
2.5%; adjusted OR 0.68; 95% CI
0.31–1.48; p 0.33)
[30] Retrospective
cohort study
1934 patients who
underwent CABG, valve
surgery or a combination of
both
SUs: 1248
NSUs: 686
Preoperative statin use was
associated with a signiﬁcant
reduction in the development of
infection (adjusted OR 0.67;
95% CI 0.46–0.99; p 0.04)
Statin use was not associated with
a signiﬁcant reduction in any
individual infection (p >0.08 for
all), such as pneumonia, urinary
tract infection, bacteraemia, deep
sternal wound infection, leg vein
harvest site infection, and
tracheotomy site infection
[31] Retrospective
cohort study
10 782 patients who
underwent inguinal
herniorrhaphy or ventral
hernia repair at ten VA
Medical Centers in the
mid-south region of the USA
SUs: 1242
NSUs: 9540
Statin use did not affect the risk
of wound infection (0.6% vs. 0.5%)
Statin use remained signiﬁcant as an
independent predictor of wound
haematoma/postoperative bleeding
(OR 1.6; 95% CI 1.03–2.44;
p 0.04)
CABG, coronary artery bypass grafting; NSU, non-statin user; SU, statin user; VA, Veterans Affairs.
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users and 10 888 non-statin users). Two of the studies
focused on patients who underwent cardiac operations; in
the ﬁrst study, among 2497 adult patients who underwent
isolated CABG, statin use did not seem to reduce the inci-
dence of serious infections (e.g. mediastinitis, sepsis syn-
drome, or septic shock) [29], whereas in the second study,
among 1934 patients who underwent CABG, valve surgery,
or a combination of both, preoperative statin use was associ-
ated with a signiﬁcant reduction in the development of infec-
tion, even though it did not lead to a statistically signiﬁcant
reduction in any individual type of infection [30]. In the larg-
est study, and the only one in this group that used propen-
sity score analysis, patients who underwent inguinal
herniorrhaphy or ventral hernia repair did not seem to bene-
ﬁt from statin use as far as the risk of wound infection is
concerned [31].
Overall, data regarding mortality as the main outcome
were presented in 15 studies; speciﬁcally, in six of nine sep-
sis studies [10–13,15,16,18], in six of seven CAP studies
[19–23,25], in three of three bacteraemia studies [26–28],
and in none of the three studies conducted in the postoper-
ative setting. Ten of these 15 studies reported decreased
mortality in statin users (three of six sepsis studies
[10,12,15], ﬁve of six CAP studies [19–22,25], and two of
three bacteraemia studies [27,28]), four of 15 studies
showed no difference in mortality (two of six sepsis studies
[11,13], one of six CAP studies [23], and one of three bac-
teraemia studies [26]), and in one study that included septic
ICU patients, there was increased mortality in those patients
who received statins [16]. In addition, nine studies (six of
nine sepsis studies [12–14,16–18] and all studies conducted
in the postoperative setting [29–31]) examined the risk of
developing sepsis/infection as the primary outcome. Five of
these nine studies showed a decreased risk of sepsis in
patients receiving statins (four of six sepsis studies
[13,14,17,18] and one of three studies conducted in the
postoperative setting [30]), whereas the remaining four stud-
ies found no difference [12,16,29,31].
Finally, regarding studies that used propensity score tech-
niques, six of eight studies reported that statin use was asso-
ciated with favourable outcomes [14,15,17,19,20,25],
whereas in the remaining two studies no difference was
shown [23,29]. Both case–control studies reported positive
results [22,24], whereas the ﬁndings of the small randomized
controlled trial cannot be safely taken into account, as they
represented secondary outcomes [12]. Among the remaining
11 studies that implemented a non-matched design, seven
reported positive ﬁndings [10,13,18,21,27,28,30], three found
no difference in outcomes [11,26,31], and one reported
worse outcomes among statin users [16]. Overall, the differ-
ence in the study design (matched vs. non-matched) did not
seem to have an effect on the reported ﬁndings.
Randomized controlled studies (unpublished and/or
ongoing) examining the use of statins in sepsis
We identiﬁed seven studies relevant to our review [37–43]
in the online registries of RCTs (http://www.clinicaltrials.gov
and http://www.controlled-trials.com). Two of them have
been completed [37,38], but their ﬁndings have not been
published yet, and the remaining ﬁve trials are still ongoing
(four of them are currently recruiting patients [39–43]).
Discussion
In this review, we attempted to identify, and present a syn-
thesis of, the available literature regarding the use of statins
for the management of septic patients. Approximately two-
thirds of the 22 evaluable studies suggested a statistically sig-
niﬁcant positive effect of statins in patients with sepsis and
infection (as exempliﬁed by decreased mortality rates in ten
of 15 studies and decreased risk of infection in ﬁve of nine
studies). Although our review cannot be considered to be
immune to publication bias, it includes all recently published
studies and corroborates the ﬁndings of previously con-
ducted reviews on the same topic [9].
The major limitation of this review is the inclusion—with
one exception [12]—of only observational cohort studies, in
which statins were administered for cardiovascular system
protection but not for the treatment of an infection. As pre-
viously noted, even in the one RCT [12] in which statins
were, in a sense, administered for treatment, as they were
started in the hospital setting, the primary endpoints were
the functional/neurological outcomes of patients with sub-
arachnoid haemorrhage, not the infection rate and its associ-
ated mortality. In addition, these studies were markedly
heterogeneous regarding: (i) their design (matched (RCT,
case–control and propensity-matched cohorts) vs. non-
matched cohorts); (ii) the sample size (i.e. 53 vs. 69 168
patients); (iii) the characteristics of the included patient pop-
ulations (i.e. healthy population-based vs. chronic haemodial-
ysis patients); (iv) the method used for data abstraction (i.e.
direct chart review vs. mining computerized databases); (v)
the deﬁnition used for current statin use (i.e. prescription
ﬁlled in the last 30 days vs. 365 days before the septic epi-
sode, and the validation or not of compliance with statin
therapy); (vi) the deﬁnition used for each infection (i.e. clini-
cally diagnosed vs. radiologically conﬁrmed pneumonia); (vii)
type and severity of the infection under study (i.e. pneumo-
nia vs. wound infection or patients treated in the community
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vs. ward-admitted patients); (viii) the implemented therapies
(i.e. adequacy of antibiotic coverage); and (ix) the reported
outcomes (i.e. hospital mortality vs. ICU admission rate).
It is of interest that the design of the included studies
(matched vs. non-matched) did not seem to explain the het-
erogeneity of the reported ﬁndings. The multidimensional
heterogeneity of the reviewed studies did not allow us to
perform a formal meta-analysis and draw ﬁrm conclusions.
This does not mean that beneﬁcial effects of statins on sepsis
can be easily written off.
The authors of the individual studies were aware of the
limitations of their analyses, and employed different tech-
niques to overcome them. For example, some of the
cohort studies used prospective data collection, but their
ﬁndings did not differ from those of retrospective cohort
studies. The most widely discussed limitation of the obser-
vational studies exploring the role of statins in sepsis is
the confounding by indication for treatment, alternatively
called the ‘healthy user effect’ [23,44,45]. This is actually a
selection bias; plainly speaking, statin users are not the
same as non-statin users. It is reasonable to hypothesize
that statin use is more likely among health-conscious
patients who have healthy diets, exercise regularly, receive
ﬂu shots, do not stop smoking, keep their appointments
with doctors, and adhere to prescribed therapies [45]. On
the other hand, it should not be forgotten that statin pre-
scription is not merely a lifestyle intervention; statin users
usually demonstrate higher cardiovascular morbidity, and
this may inﬂuence their outcome in a negative way during
an infectious complication.
The authors of some studies attempted to control for the
healthy user effect by using propensity scoring. In this
statistical technique, which was developed 25 years ago [46],
multivariable logistic regression analysis is used to estimate
the probability of use of an intervention (e.g. insertion of
Swan–Ganz catheters) or a drug (e.g. statin) on the basis of
preselected patient characteristics. The propensity score is
the probability of exposure to this intervention, given the
observed parameters, and it may reduce selection bias in
trials with non-randomized designs. It is of note that
approximately two-thirds of the studies that were included
in our review and used propensity-matched subcohorts
reported that statin use was associated with positive
outcomes.
As propensity scoring cannot fully rule out the possibility
of confounding by unmeasured factors or replace randomiza-
tion, large RCTs have been designed to better deﬁne the
effects of statins on sepsis incidence and outcomes. The
recent paradigms of hormone replacement therapy in post-
menopausal women [47] and antioxidant supplementation
for cancer prevention [48] that—despite promising data
from observational studies—failed to show efﬁcacy in RCTs
serve as useful reminders. As previously mentioned, two
randomized double-blind placebo-controlled trials have
already been completed, and await publication; the ﬁrst
explored whether the administration of simvastatin to ICU-
admitted patients with severe sepsis reduced plasma concen-
trations of interleukin-6 and improved clinical endpoints
[37], and the second explored whether the use of atorvasta-
tin in ward patients with sepsis can signiﬁcantly reduce the
rates of conversion from sepsis to severe sepsis and other
‘hard’ clinical outcomes [38]. Five additional studies have still
to be completed [39–43], conﬁrming the keen interest of
the pharmaceutical industry and the medical community in
this issue.
Notwithstanding the merits of the expected RCTs, we
think that their ﬁndings, either positive or negative, should
be viewed with caution for several reasons. First, RCTs are
not immune to unequal (chance-dependent) distribution of
variables between the intervention and the control groups.
Second, not all statins have been created equal, and their
anti-inﬂammatory properties are known to vary, at least in
animals [49]. Third, few preclinical studies have tested their
administration after the infectious challenge, and the corre-
sponding results are contradictory [49,50]. In that regard,
one might consider numerous and costly RCTs to be prema-
ture and unjustiﬁed. Fourth, statins may not be effective
among all patient subpopulations. A 70-year-old man with
underlying coronary artery disease admitted to the ICU with
pneumonia, acute respiratory distress syndrome and septic
shock may not derive the same beneﬁt from statin use as an
otherwise healthy 55-year-old woman with pyelonephritis.
Fifth, the erratic and unpredictable gastrointestinal drug
absorption in critically ill patients, combined with the
absence (so far) of intravenous statin formulations, will seri-
ously limit their applicability in the ICU setting [51]. Finally,
critically ill patients may be at a heightened risk of statin-
associated myopathy and hepatotoxicity resulting from
pre-existing comorbidities, intervening organ failures (e.g.
renal failure), and polypharmacy (e.g. steroids, macrolides,
amiodarone, and muscle relaxants) [51]. These adverse
events may easily shift the therapeutic pendulum from a
potentially positive effect to a harmful complication.
Conclusion
The last decade has witnessed an increasing interest in the
use of statins for the prevention and/or treatment of infec-
tions. The majority of the available literature lends support
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to a potentially positive effect of statin administration.
Unfortunately, it is mostly of an observational nature, and
therefore may suffer from selection bias and hidden con-
founding. The harsh reality is that there is no strong clinical
evidence to support the routine use of statins in septic
patients. However, before throwing the baby out with the
bathwater, we should await the results of large RCTs yield-
ing clinically exploitable conclusions.
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